236 related articles for article (PubMed ID: 6827175)
1. Leukemia-associated antigens in leukemic transformation of polycythemia vera.
Pisciotta AV; Cronkite C; Hanson GA; Brodsky JB; Donovan PB; Wasserman LR
J Lab Clin Med; 1983 Mar; 101(3):432-40. PubMed ID: 6827175
[TBL] [Abstract][Full Text] [Related]
2. Quantitative and functional studies of impaired natural killer (NK) cells in patients with myelofibrosis, essential thrombocythemia, and polycythemia vera. I. A potential role for platelet-derived growth factor in defective NK cytotoxicity.
Gersuk GM; Carmel R; Pattamakom S; Challita PM; Rabinowitz AP; Pattengale PK
Nat Immun; 1993; 12(3):136-51. PubMed ID: 8329837
[TBL] [Abstract][Full Text] [Related]
3. Specificity of heteroantisera to human acute leukemia-associated antigens.
Baker MA; Ramachandar K; Taub RN
J Clin Invest; 1974 Dec; 54(6):1273-8. PubMed ID: 4140196
[TBL] [Abstract][Full Text] [Related]
4. Leukemogenic risk of hydroxyurea therapy in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis.
Nand S; Stock W; Godwin J; Fisher SG
Am J Hematol; 1996 May; 52(1):42-6. PubMed ID: 8638610
[TBL] [Abstract][Full Text] [Related]
5. Antigenic characteristics of erythropoietin dependent and independent erythroid progenitors (BFU-E and CFU-E) in polycythaemia vera and idiopathic myelofibrosis defined by monoclonal antibodies.
Robak T
Arch Immunol Ther Exp (Warsz); 1988; 36(6):733-47. PubMed ID: 3254121
[TBL] [Abstract][Full Text] [Related]
6. Antigenic characteristics of circulating granulocyte-macrophage progenitors (CFU-GM) in idiopathic myelofibrosis and polycythaemia vera defined by monoclonal antibodies.
Robak T
Arch Immunol Ther Exp (Warsz); 1989; 37(1-2):17-28. PubMed ID: 2619501
[TBL] [Abstract][Full Text] [Related]
7. [CD7+, CD34+, electronmicroscopically peroxidase-negative acute leukemia transformed from polycythemia vera after 12 years follow-up].
Kuno Y; Takeo T; Kawashima K
Rinsho Ketsueki; 1997 Sep; 38(9):782-7. PubMed ID: 9364871
[TBL] [Abstract][Full Text] [Related]
8. [Rapidly progressive fibrosis and increased CD68-positive cells in the bone marrow at the terminal stage of adult T-cell leukemia accompanied by polycythemia vera].
Otawa M; Kawanishi Y; Ando K; Iwama H; Shohji N; Nishimaki J; Tauchi T; Miyazawa K; Kimura Y; Serizawa H; Ohyashiki K
Rinsho Ketsueki; 2000 Dec; 41(12):1254-9. PubMed ID: 11201150
[TBL] [Abstract][Full Text] [Related]
9. The role of beta-catenin in chronic myeloproliferative disorders.
Jauregui MP; Sanchez SR; Ewton AA; Rice L; Perkins SL; Dunphy CH; Chang CC
Hum Pathol; 2008 Oct; 39(10):1454-8. PubMed ID: 18619646
[TBL] [Abstract][Full Text] [Related]
10. [Novel method in diagnosis of chronic myeloproliferative disorders--detection of JAK2 mutation].
Rajnai H; Bödör C; Reiniger L; Timár B; Csernus B; Szepesi A; Csomor J; Matolcsy A
Orv Hetil; 2006 Nov; 147(45):2175-9. PubMed ID: 17402211
[TBL] [Abstract][Full Text] [Related]
11. Sequential development of chronic lymphocytic leukemia in a patient with polycythemia vera.
Koza I; Babusíková O
Neoplasma; 1988; 35(1):77-80. PubMed ID: 3352840
[TBL] [Abstract][Full Text] [Related]
12. [Successful treatment with interferon-alpha in a case of acute myeloid leukemia with del (20q) following polycythemia vera].
Sumi M; Tauchi T; Takaku T; Ohyashiki JH; Ohyashiki K
Rinsho Ketsueki; 2005 Nov; 46(11):1208-12. PubMed ID: 16440805
[TBL] [Abstract][Full Text] [Related]
13. [30 cases of myeloid metaplasia and 5 cases of acute leukemia in a group of 200 cases of polycythemia vera].
Nicoară S; Butoianu E; Ciocoiu A; Coliţă A; Grigoriu G; Vîlcu A; Ursea C; Dosius L; Niculescu R
Rev Med Interna Neurol Psihiatr Neurochir Dermatovenerol Med Interna; 1983; 35(3):261-6. PubMed ID: 6140721
[No Abstract] [Full Text] [Related]
14. [The risk factors for thrombosis, myelofibrosis and leukemia transformation in patients with polycythemia vera].
Bai J; Xue YP; Ye L; Yao JF; Zhou CL; Qian LS; Yang RC; Li HY; Zhang HY; Shao ZH
Zhonghua Xue Ye Xue Za Zhi; 2007 Oct; 28(10):685-8. PubMed ID: 18399175
[TBL] [Abstract][Full Text] [Related]
15. Vascular and neoplastic risk in a large cohort of patients with polycythemia vera.
Marchioli R; Finazzi G; Landolfi R; Kutti J; Gisslinger H; Patrono C; Marilus R; Villegas A; Tognoni G; Barbui T
J Clin Oncol; 2005 Apr; 23(10):2224-32. PubMed ID: 15710945
[TBL] [Abstract][Full Text] [Related]
16. [Karyotype studies in primary polycythemia vera (author's transl)].
Berger R; Parmentier C; Droz JP
Nouv Rev Fr Hematol; 1974; 14(6):705-12. PubMed ID: 4282500
[No Abstract] [Full Text] [Related]
17. Risk factors for leukemic transformation in patients with primary myelofibrosis.
Huang J; Li CY; Mesa RA; Wu W; Hanson CA; Pardanani A; Tefferi A
Cancer; 2008 Jun; 112(12):2726-32. PubMed ID: 18404742
[TBL] [Abstract][Full Text] [Related]
18. Leukocyte-platelet interaction in patients with essential thrombocythemia and polycythemia vera.
Falanga A; Marchetti M; Vignoli A; Balducci D; Barbui T
Exp Hematol; 2005 May; 33(5):523-30. PubMed ID: 15850829
[TBL] [Abstract][Full Text] [Related]
19. 20+ yr without leukemic or fibrotic transformation in essential thrombocythemia or polycythemia vera: predictors at diagnosis.
Tefferi A; Gangat N; Wolanskyj AP; Schwager S; Pardanani A; Lasho TL; Mesa R; McClure RF; Li CY; Hanson CA
Eur J Haematol; 2008 May; 80(5):386-90. PubMed ID: 18221390
[TBL] [Abstract][Full Text] [Related]
20. [Leukemic transformation of polycythemia vera after treatment with hydroxyurea and chromosome 17 abnormalities].
Tóthová E; Nebesnáková E; Kafková A; Stecová N; Fricová M
Vnitr Lek; 1999 Aug; 45(8):487-9. PubMed ID: 11045151
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
